Earlier quoted context omitted.
But for an insurance company, the ROI on curing someone’s hemophilia may be very very large. On the more consumer side of things, being able to fix some sort of obnoxious but perfectly survivable condition that genetic engineering may be able to solve (say lactose intolerant) may be something that you could sell to a lot of people.
From the POV of an insurance company, the patient might go elsewhere in a few years and they would only partially benefit from a cure.
Haemophilia A trial results 'mind-blowing'
111–120 of 132 posts
Re: Haemophilia A trial results 'mind-blowing'
#112It is hard to target gene therapy toward specific cells/tissues but the liver makes targeting haemophilia with gene therapy easier.
Re: Haemophilia A trial results 'mind-blowing'
#113Earlier quoted context omitted.
Doesn't make much sense when my eyes were blue as a kid, but now are green except for a quarter of one eye which is brown.
Brown, green, hazel eye colors are variations in the amount on melanin in the iris. This amount can change as one gets older. Babies can have lighter eyes that become darker. Blue eyes are believed to be caused by an isolated, inherited gene, OCA2. This gene is present in all people that have blue eyes. It disables the production of melanin in the iris. All blue eyed people are believed to have a common ancestor from…
I ask because my niece had blue eyes as a baby. This didn't make any sense because my sister was Indian, our parents were from India, their parents were from .. well I guess now it's Pakistan, but they migrated during the partition.
My sister married a white dude, but still it seemed very unlikely her daughter wouldn't have brown eyes. That's when we found out my grandmother got her education in Europe, and came back pregnant. Apparently divorces at the time were so shameful that it was better to tell your child their parent died.
My nieces eyes are now a bit hazel/blue-green ish. My grandmother passed away not too long after that, and that secret would have died with her, if it wasn't for the fact that my niece had blue eyes.
Re: Haemophilia A trial results 'mind-blowing'
#114Earlier quoted context omitted.
Is the virus transmissible?
The study did not look at whether family members or other close acquaintances ended up containing measurable numbers of copies of the virus. The patients were tested and the study verified that the (altered) genetic data from the virus was excreted normally. The virus was deliberately defective and unable to replicate, so the copies made for use in treatment are the only copies that would ever exist. This also ensure…
Re: Haemophilia A trial results 'mind-blowing'
#115Re: Haemophilia A trial results 'mind-blowing'
#116Earlier quoted context omitted.
Brown, green, hazel eye colors are variations in the amount on melanin in the iris. This amount can change as one gets older. Babies can have lighter eyes that become darker. Blue eyes are believed to be caused by an isolated, inherited gene, OCA2. This gene is present in all people that have blue eyes. It disables the production of melanin in the iris. All blue eyed people are believed to have a common ancestor from…
huh. So where does the dominant/recessive traits we learn about in high school play into that? I ask because my niece had blue eyes as a baby. This didn't make any sense because my sister was Indian, our parents were from India, their parents were from .. well I guess now it's Pakistan, but they migrated during the partition. My sister married a white dude, but still it seemed very unlikely her daughter wouldn't have…
Re: Haemophilia A trial results 'mind-blowing'
#117Re: Haemophilia A trial results 'mind-blowing'
#118Science, it works bitches.
Re: Haemophilia A trial results 'mind-blowing'
#119Earlier quoted context omitted.
I sincerely think we are in the gene therapy renaissance. Delivery has always been an issue, but there are new tricks coming out with regard to cell-specific targeting. We can piggy back off the work done for RNA-based therapeutics (mRNA, ASOs, RNAi). As for the CNS - Voyager therapeutics has had some great readouts in September in gene therapy for Parkinson's. More data coming out in Q1 to see second part of study.
i agree, the hemophilia data looks really good, and avexis' spinal muscular atrophy product looks great as well. i dont know much about voyager but just looked at their press release for the study; looks like they are delivering a gene to increase dopamine production? do you know if this could be a disease altering therapy or just a "better" levodopa? its still pretty hard from what i can tell to deliver oligos to sp…
Also correct about general delivery difficulties. Hadn't heard of Biontech's method - almost sounds like voodoo by your description.
I think there is interesting blocking and tackling happening on an organ-by-organ basis. E.g. GalNAc for liver hepatocytes, LNPs for systemic mRNA therapies, direct injection for eye or CNS (cheating, but still works). I'm partial to exosome hype...
Also no such discussion is complete without saying CRISPR, but the point remains that you can conjugate it targetted vehicles like antibodies. Conjugating to antibodies seemed to work for Stem :p
Re: Haemophilia A trial results 'mind-blowing'
#120Another use of a modified virus is to deliver an antibody to VEGF, the factor that causes macular degeneration (blindness). Prof. Elizabeth Rakoczy has been recently awarded the 2017 CSL Florey medal for this work. http://www.aips.net.au/news-events/the-florey-medal/2017-pro... The video has a cartoon showing the modified virus being inserted in the retina. I think 40 patients have been successfully treated in a init…
The figure that jumps out of the page for me in the modified-virus report, http://www.aips.net.au/news-events/the-florey-medal/2017-pro..., is "This therapy has been licensed to US company Avalanche Biotechnologies Inc., which has raised over $400 million to progress the treatment through clinical trials and bring it to market." This figure of US$400 million takes my breath away. I note one of Prof. Rakoczy's clinical trials in Australia on 32 patients was done with a AU$370 thousand grant, among others, https://demo.ands.org.au/long-term-follow-gene-therapy/10789.... I guess the US$400 million trial will be more extensive. This means a few more years will have to go by before this comes to market (if it indeed does).
I have found an open source article about Prof. Rakoczy's trial, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161436/. I note they removed the vitreous humor to place the modified-virus under the retina (termed a vitrectomy), recording that "It is not yet clear if subretinal injection can be done safely without vitrectomy". They seem very pleased with the results of that phase 2 trial.